DexCom, Inc. (DXCM)

[TREND1]

DexCom, Inc. (Nasdaq: DXCM) today reported preliminary unaudited revenues of approximately $105 million for the quarter ended September 30, 2015, an increase of $36 million, or 52%, year over year. Dexcom’s third quarter 2015 revenues are preliminary and subject to adjustment as the Company evaluates the impact of any revenue deferral related to the upgrade programs announced in connection with the Company’s G5 Mobile launch.

“Our third quarter revenues again exceeded our expectations and we couldn’t be more pleased with the performance of our organization,” said Kevin Sayer, Dexcom’s President and Chief Executive Officer. “Demand for our G5 Mobile system has been overwhelming and our pipeline of new patient opportunities is larger than it has ever been. We have worked diligently to fulfill demand by new patients, we have commenced shipping upgrades to existing patients and we expect to complete the upgrade cycle before the end of 2015. There has been some noise in the marketplace recently suggesting that certain payers are seeking to delay payment for CGM, and while we have always stated that payers can be challenging from time to time, we could not deliver a record quarter in terms revenues without meaningful contribution from all major payers.”